Harvard Bioscience (HBIO) 10-Q 8 May 20 2020 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2020	Apr. 30, 2020
Document Information [Line Items]
Entity Registrant Name	HARVARD BIOSCIENCE INC
Entity Central Index Key	0001123494
Trading Symbol	hbio
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		38,380,403
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Mar. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Amendment Flag	false
Title of 12(b) Security	Common Stock, $0.01 par value

Consolidated Balance Sheets (Cu

Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 5,882	$ 8,335
Accounts receivable, net	15,425	20,704
Inventories	23,143	22,061
Other current assets	3,715	2,472
Total current assets	48,165	53,572
Property, plant and equipment, net	4,488	4,776
Operating lease right-of-use assets	8,127	8,463
Goodwill	56,792	57,381
Intangible assets, net	36,807	38,405
Other long-term assets	1,881	2,273
Total assets	156,260	164,870
Current liabilities:
Current portion of long-term debt	2,807	6,900
Current portion of operating lease liabilities	2,297	2,424
Accounts payable	6,625	5,339
Deferred revenue	3,673	3,949
Accrued income taxes	624	609
Other current liabilities	7,449	6,091
Total current liabilities	23,475	25,312
Long-term debt	46,280	46,917
Deferred tax liability	1,767	1,974
Operating lease liabilities	7,867	8,224
Other long-term liabilities	862	749
Total liabilities	80,251	83,176
Commitments and contingencies
Stockholders' equity:
Preferred stock, par value $0.01 per share, 5,000,000 shares authorized
Common stock, par value $0.01 per share, 80,000,000 shares authorized; 46,120,640 and 45,933,715 shares issued and 38,375,133 and 38,188,208 shares outstanding, respectively	438	438
Additional paid-in-capital	229,740	229,189
Accumulated deficit	(129,092)	(124,576)
Accumulated other comprehensive loss	(14,409)	(12,689)
Treasury stock at cost, 7,745,507 common shares	(10,668)	(10,668)
Total stockholders' equity	76,009	81,694
Total liabilities and stockholders' equity	$ 156,260	$ 164,870

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2020	Dec. 31, 2019
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	80,000,000	80,000,000
Common stock, shares issued (in shares)	46,120,640	45,933,715
Common stock, shares outstanding (in shares)	38,375,133	38,188,208
Treasury stock, common shares (in shares)	7,745,507	7,745,507

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenues	$ 23,771	$ 28,202
Cost of revenues	10,789	12,048
Gross profit	12,982	16,154
Sales and marketing expenses	5,579	6,306
General and administrative expenses	6,759	5,803
Research and development expenses	2,490	2,735
Amortization of intangible assets	1,427	1,430
Total operating expenses	16,255	16,274
Operating loss	(3,273)	(120)
Other expense:
Interest expense, net	(1,299)	(1,405)
Other (income) expense, net	111	(269)
Total other expense	(1,188)	(1,674)
Loss before income taxes	(4,461)	(1,794)
Income tax expense	55	576
Net loss	$ (4,516)	$ (2,370)
Loss per share:
Basic loss per common share (in dollars per share)	$ (0.12)	$ (0.06)
Diluted loss per common share (in dollars per share)	$ (0.12)	$ (0.06)
Weighted-average common shares:
Basic (in shares)	38,328,791	37,644,684
Diluted (in shares)	38,328,791	37,644,684
Net Loss	$ (4,516)	$ (2,370)
Other comprehensive (loss):
Foreign currency translation adjustments	(1,576)	4
Derivatives qualifying as hedges, net of tax:
(Loss) gain on derivative instruments designated and qualifying as cash flow hedges	(216)	(196)
Amounts reclassified from accumulated other comprehensive loss to net loss	72	17
Derivatives qualifying as hedges, net of tax	(144)	(179)
Other comprehensive (loss)	(1,720)	(175)
Comprehensive loss	$ (6,236)	$ (2,545)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Treasury Stock [Member]	Total
Balance (in shares) at Dec. 31, 2018	45,124
Balance at Dec. 31, 2018	$ 436	$ 226,377	$ (119,889)	$ (13,532)	$ (10,668)	$ 82,724
Vesting of restricted stock units (in shares)	440
Vesting of restricted stock units
Shares withheld for taxes (in shares)	(134)
Shares withheld for taxes		(429)				(429)
Stock compensation expense		591				591
Net (loss) income			(2,370)			(2,370)
Other comprehensive loss				(175)		(175)
Stock option exercises (in shares)	3
Stock option exercises		8				8
Net Loss			(2,370)			(2,370)
Balance (in shares) at Mar. 31, 2019	45,433
Balance at Mar. 31, 2019	$ 436	226,547	(122,259)	(13,707)	(10,668)	80,349
Balance (in shares) at Dec. 31, 2019	45,934
Balance at Dec. 31, 2019	$ 438	229,189	(124,576)	(12,689)	(10,668)	81,694
Vesting of restricted stock units (in shares)	268
Vesting of restricted stock units
Shares withheld for taxes (in shares)	(81)
Shares withheld for taxes		(242)				(242)
Stock compensation expense		793				793
Net (loss) income			(4,516)			(4,516)
Other comprehensive loss				(1,720)		(1,720)
Net Loss			(4,516)			(4,516)
Balance (in shares) at Mar. 31, 2020	46,121
Balance at Mar. 31, 2020	$ 438	$ 229,740	$ (129,092)	$ (14,409)	$ (10,668)	$ 76,009

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash flows from operating activities:
Net Loss	$ (4,516)	$ (2,370)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation	484	538
Amortization of intangible assets	1,427	1,430
Amortization of deferred financing costs	98	91
Stock-based compensation expense	793	591
Provision for allowance for doubtful accounts	4	348
Other non-cash charges	(166)	4
Changes in operating assets and liabilities:
Accounts receivable	5,149	2,331
Inventories	(1,413)	(1,416)
Other current assets	(767)	536
Accounts payable	1,322	(118)
Accrued income taxes	6	380
Other current liabilities	1,411	(76)
Deferred revenue	(256)	(116)
Other long-term liabilities	(705)	(143)
Net cash provided by operating activities	2,871	2,010
Cash flows from investing activities:
Additions to property, plant and equipment	(241)	(143)
Other		(9)
Net cash used in investing activities	(241)	(152)
Cash flows from financing activities:
Repayments of debt	(4,829)	(4,583)
Taxes paid for issuance of stock	(242)	(421)
Net cash used in financing activities	(5,071)	(5,004)
Effect of exchange rate changes on cash	(12)	3
Decrease in cash and cash equivalents	(2,453)	(3,143)
Cash and cash equivalents at beginning of period	8,335	8,173
Cash and cash equivalents at end of period	5,882	5,030
Supplemental disclosures of cash flow information:
Cash paid for interest	1,237	1,406
Cash paid for income taxes	$ 110	$ 94

Note 1 - Basis of Presentation,

Note 1 - Basis of Presentation, Risks and Uncertainties, and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	1. Basis of Presentation, Risks and Uncertainties, and Summary of Significant Accounting Policies Basis of Presentation The unaudited consolidated financial statements of Harvard Bioscience, Inc. and its wholly-owned subsidiaries (collectively, Harvard Bioscience or the Company) as of March 31, 2020 three March 31, 2020 2019, December 31, 2019 not not 10 December 31, 2019, March 16, 2020. In the opinion of management, all adjustments, which include normal recurring adjustments necessary to present a fair statement of financial position as of March 31, 2020, three March 31, 2020 2019 three March 31, 2020 2019, three March 31, 2020 not Risks and Uncertainties On March 11, 2020, 19 19 19 As a result of these market and economic conditions, in accordance with the guidelines set forth in ASC 350 360, March 31, 2020, no 19. 2020. Summary of Significant Accounting Policies The accounting policies underlying the accompanying unaudited consolidated financial statements are those set forth in Note 2 10 December 31, 2019, March 16, 2020. no three March 31, 2020.

Note 2 - Recently Issued Accoun

Note 2 - Recently Issued Accounting Pronouncements	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Description of New Accounting Pronouncements Not yet Adopted [Text Block]	2. Recently Issued Accounting Pronouncements Accounting Pronouncements to be Adopted In June 2016, No. 2016 13, Financial Instruments—Credit Losses (Topic 326 may 2016 13 2016 13 December 15, 2022, 2016 13 In August 2018, No. 2018 14, Disclosure Framework—Changes to the Disclosure Requirements for Defined Benefit Plans 715 December 15, 2020, not In December 2019, 2019 12, Income Taxes (Topic 740 2019 12 2019 12 January 1, 2021.

Note 3 - Accumulated Other Comp

Note 3 - Accumulated Other Comprehensive Loss	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Comprehensive Income (Loss) Note [Text Block]	3. Accumulated Other Comprehensive Loss Changes in each component of accumulated other comprehensive loss, net of tax are as follows: Foreign currency Derivatives translation qualifying as Defined benefit (in thousands) adjustments hedges pension plans Total Balance at December 31, 2019 $ (13,173 ) $ (603 ) $ 1,087 $ (12,689 ) Other comprehensive (loss) income before reclassifications (1,576 ) (216 ) (1,792 ) Amounts reclassified from AOCI into Income - 72 72 Net other comprehensive (loss) income (1,576 ) (144 ) - (1,720 ) Balance at March 31, 2020 $ (14,749 ) $ (747 ) $ 1,087 $ (14,409 )

Note 4 - Goodwill and Intangibl

Note 4 - Goodwill and Intangible Assets	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	4. Goodwill and Intangible Assets Goodwill The change in the carrying amount of goodwill for the three March 31, 2020 March 31, 2020 (in thousands) Balance at December 31, 2019 $ 57,381 Effect of change in currency translation (589 ) Balance at March 31, 2020 $ 56,792 Intangible Assets March 31, 2020 December 31, 2019 (in thousands) Intangible assets: Weighted Gross Accumulated Net Gross Accumulated Net Distribution agreements/customer relationships 8.4 $ 17,685 $ (6,550 ) $ 11,135 $ 17,891 $ (6,340 ) $ 11,551 Existing technology 5.5 40,923 (20,327 ) 20,596 41,222 (19,698 ) 21,524 Trade names 5.3 8,511 (3,667 ) 4,844 7,692 (3,497 ) 4,195 Patents - 206 (206 ) - 218 (218 ) - Indefinite-lived tradename NA 232 - 232 1,135 0 1,135 Total intangible assets $ 67,557 $ (30,750 ) $ 36,807 $ 68,158 $ (29,753 ) $ 38,405 * Weighted average life as of March 31, 2020. During the three March 31, 2020, $0.9 4 Intangible asset amortization expense was $1.4 three March 31, 2020 2019. $4.1 2020, $5.5 December 31, 2021, $5.5 December 31, 2022, $5.3 December 31, 2023, $5.3 December 31, 2024, $4.2 December 31, 2025.

Note 5 - Inventories

Note 5 - Inventories	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Inventory Disclosure [Text Block]	5. Inventories Inventories consist of the following: March 31, December 31, (in thousands) Finished goods $ 5,280 $ 5,561 Work in process 3,160 3,153 Raw materials 14,703 13,347 Total $ 23,143 $ 22,061

Note 6 - Property, Plant and Eq

Note 6 - Property, Plant and Equipment	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	6. Property, Plant and Equipment Property, plant, and equipment consist of the following: March 31, December 31, (in thousands) Machinery and equipment $ 7,437 $ 7,198 Computer equipment and software 8,763 8,954 Leasehold improvements 2,157 2,151 Furniture and fixtures 1,309 1,321 Automobiles 90 92 19,756 19,716 Less: accumulated depreciation (15,268 ) (14,940 ) Property, plant and equipment, net $ 4,488 $ 4,776

Note 7 - Restructuring and Othe

Note 7 - Restructuring and Other Exit Costs	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Restructuring and Related Activities Disclosure [Text Block]	7. Restructuring and Other Exit Costs During 2019, The restructuring program is expected to be completed by the end of 2020. The following table summarizes the activity for the accrued restructuring liability for the three March 31, 2020: (in thousands) Severance Other Total Balance at December 31, 2019 $ 364 $ 4 $ 368 Restructuring charges 834 40 874 Adjustments (45 ) - (45 ) Cash payments (569 ) (36 ) (605 ) Balance at March 31, 2020 $ 584 $ 8 $ 592 As of March 31, 2020, $0.6 twelve

Note 8 - Related Party Transact

Note 8 - Related Party Transactions	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	8. Related Party Transactions As part of the acquisitions of Multi Channel Systems MCS GmbH (MCS) and Triangle BioSystems, Inc. (TBSI) in 2014, $0.1 three March 31, 2020 2019.

Note 9 - Employee Benefit Plans

Note 9 - Employee Benefit Plans	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Retirement Benefits [Text Block]	9. Employee Benefit Plans The Company’s subsidiary in the United Kingdom, Biochrom Limited, maintains two 2014, For the three March 31, 2020 2019, $0.1 $0.2 three March 31, 2020 2019, $0.2 $0.7 2020. December 31, 2019, $1.1

Note 10 - Leases

Note 10 - Leases	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	10. Leases The Company has noncancelable operating leases for office, manufacturing facilities, warehouse space, automobiles and equipment expiring at various dates through 2024 The components of lease expense for the three March 31, 2020 2019 Three Months Ended Three Months Ended March 31, 2020 March 31, 2019 (in thousands) (in thousands) Operating lease cost $ 535 $ 523 Short term lease cost 42 76 Sublease income (107 ) (102 ) Total lease cost $ 470 $ 497 Supplemental cash flow information related to the Company's operating leases was as follows: Three Months Ended Three Months Ended March 31, 2020 March 31, 2019 (in thousands) (in thousands) Cash paid for amounts included in the measurement $ 687 $ 702 Supplemental balance sheet information related to the Company's operating leases was as follows: March 31, 2020 December 31, 2019 (in thousands) (in thousands) Operating lease right-of use assets $ 8,127 $ 8,463 Current portion, operating lease liabilities $ 2,297 $ 2,424 Operating lease liabilities, long term 7,867 8,224 Total operating lease liabilities $ 10,164 $ 10,648 Weighted average remaining lease term (in years) 8.0 8.1 Weighted average discount rate 9.2 % 9.2 % Future minimum lease payments for operating leases, with initial or remaining terms in excess of one March 31, 2020, Operating Leases (in thousands) 2021 $ 2,297 2022 1,905 2023 1,842 2024 1,827 2025 1,367 Thereafter 5,574 Total lease payments 14,812 Less interest (4,648 ) Total operating lease liabilities $ 10,164

Note 11 - Capital Stock and Sto

Note 11 - Capital Stock and Stock-based Compensation	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Shareholders' Equity and Share-based Payments [Text Block]	11. Capital Stock and Stock-Based Compensation Employee Stock Purchase Plan (as amended, the ESPP) Under the Company’s ESPP, participating employees can authorize the Company to withhold a portion of their base pay during consecutive six 85% six June 30 December 31. May 16, 2019, 350,000 1,400,000 1,081,404 December 31, 2019. no March 31, 2020. March 31, 2020, 318,596 Third Amended and Restated 2000 On May 25, 2011, April 2, 2018. 2018 3,400,000 20,908,929. March 31, 2020, 275,419 Restricted Stock Units with a Market Condition (the Market Condition RSUs) In 2019, 2019 2019 one third three 2019 As of March 31, 2020, may 529,491 150% Stock-Based Payment Awards The Company accounts for stock-based payment awards in accordance with the provisions of FASB ASC 718, no Stock option and restricted stock unit activity for the three March 31, 2020 Stock Options Restricted Stock Units Market Condition RSU's Weighted Stock Average Restricted Market Options Exercise Stock Units Grant Date Condition RSU's Grant Date Outstanding Price Outstanding Fair Value Outstanding Fair Value Balance at December 31, 2019 2,266,122 $ 3.93 1,590,450 $ 2.27 529,491 $ 1.67 Granted 42,373 2.58 142,766 3.00 - - Vested (RSUs) - - (267,588 ) 2.75 - - Cancelled / forfeited (49,074 ) 3.81 (31,795 ) 3.02 - - Balance at March 31, 2020 2,259,421 $ 3.90 1,433,833 $ 2.24 529,491 $ 1.67 For the three March 31, 2020, not $3.3 two Valuation and Expense Information under Stock-Based-Payment Accounting Stock-based compensation expense for the three March 31, 2020 2019 Three Months Ended March 31, 2020 2019 (in thousands) Cost of product revenues $ 10 $ 13 Sales and marketing 51 (7 ) General and administrative 696 551 Research and development 36 34 Total stock-based compensation $ 793 $ 591 The Company did not The weighted-average estimated fair value per share of stock options granted during the three March 31, 2020 $1.18 2020 Volatility 54.83 % Risk-free interest rate 1.16 % Expected holding period (in years) 4.6 The Company used historical volatility to calculate the expected volatility as of March 31, 2020. one four ten Earnings per share Basic earnings per share is calculated by dividing net income by the number of weighted average common shares outstanding during the period. The calculation of diluted earnings per share assumes conversion of stock options, restricted stock units and Market Condition RSUs into common stock using the treasury method. The weighted average number of shares used to compute basic and diluted earnings per share consists of the following: Three Months Ended March 31, 2020 2019 Basic 38,328,791 37,644,684 Diluted 38,328,791 37,644,684 Excluded from the shares used in calculating the diluted earnings per common share in the above table are options, restricted stock units and Market Condition RSUs of approximately 4,222,745 3,691,304 three March 31, 2020 2019,

Note 12 - Long Term Debt

Note 12 - Long Term Debt	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Long-term Debt [Text Block]	12. Long term Debt On January 31, 2018, On August 16, 2018, November 4, 2019, September 30, 2019 The Financing Agreement provided for senior secured credit facilities (the Senior Secured Credit Facilities) comprised of a $64.0 $25.0 March 31, 2020, $4.6 Commencing on March 31, 2018, $0.4 three $0.6 four $0.8 2023. ten 50% three March 31, 2020, $4.0 December 31, 2019, $4.0 $1.0 The obligations of the Borrower under the Senior Secured Credit Facilities are unconditionally guaranteed by the Company and certain of the Company’s existing and subsequently acquired or organized subsidiaries. The Senior Secured Credit Facilities and related guarantees are secured on a first 65% Interest on all loans under the Senior Secured Credit Facilities is paid monthly. Borrowings under the Financing Agreement accrue interest at a per annum rate equal to, at the Borrower’s option, a base rate plus 4.75% 6.25%. 1.25% 4.25% 2021. The Financing Agreement contains customary representations and warranties and affirmative covenants applicable to the Company and its subsidiaries and also contains certain restrictive covenants, including, among others, limitations on the incurrence of additional debt, liens on property, acquisitions and investments, loans and guarantees, mergers, consolidations, liquidations and dissolutions, asset sales, dividends and other payments in respect of the Company’s capital stock, prepayments of certain debt, transactions with affiliates and modifications of organizational documents, material contracts, affiliated practice agreements and certain debt agreements. The Financing Agreement contains customary events of default and is subject to covenant and working capital borrowing restrictions. The Company is compliant with all covenants under the Financing Agreement as of March 31, 2020. The Company’s covenants include a requirement to maintain a maximum leverage ratio among other financial and non-financial covenants, as defined in the Financing Agreement. The maximum permitted leverage is the ratio of total debt to consolidated EBITDA, as defined in the Financing Agreement, with a maximum ratio of 3.50 March 31, 2020, 3.25 three June 30, 2020 19 Based on the Company’s current operating plans, including actions taken to mitigate the impact of COVID- 19, 19 19 may no As of March 31, 2020, 8.40%. As of March 31, 2020, December 31, 2019, March 31, December 31, 2020 2019 (in thousands) Long-term debt: Term loan $ 50,168 54,997 Revolving line - - Total unamortized deferred financing costs (1,081 ) (1,180 ) Total debt 49,087 53,817 Less: current installments (3,200 ) (3,200 ) Less: excess cash flow sweep - (4,093 ) Current unamortized deferred financing costs 393 393 Long-term debt $ 46,280 $ 46,917

Note 13 - Derivatives

Note 13 - Derivatives	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Derivative Instruments and Hedging Activities Disclosure [Text Block]	13. Derivatives The Company uses interest-rate-related derivative instruments to manage its exposure related to changes in interest rates on its variable-rate debt instruments. The Company does not not By using derivative financial instruments to hedge exposures to changes in interest rates, the Company exposes itself to credit risk and market risk. Credit risk is the failure of the counterparty to perform under the terms of the derivative contract. When the fair value of a derivative contract is positive, the counterparty owes the Company, which creates credit risk for the Company. When the fair value of a derivative contract is negative, the Company owes the counterparty and, therefore, the Company is not Market risk is the adverse effect on the value of a derivative instrument that results from a change in interest rates. The market risk associated with interest-rate contracts is managed by establishing and monitoring parameters that limit the types and degree of market risk that may The Company assesses interest rate risk by continually identifying and monitoring changes in interest rate exposures that may The Company uses variable-rate LIBOR debt to finance its operations. The debt obligations expose the Company to variability in interest payments due to changes in interest rates. Management believes that it is prudent to limit the variability of a portion of its interest payments. To meet this objective, management enters into LIBOR based interest rate swap agreements to manage fluctuations in cash flows resulting from changes in the benchmark interest rate of LIBOR. These swaps change the variable-rate cash flow exposure on the debt obligations to fixed cash flows. Under the terms of the interest rate swaps, the Company receives LIBOR based variable interest rate payments and makes fixed interest rate payments, thereby creating the equivalent of fixed-rate debt for the notional amount of its debt hedged. As disclosed in Note 12, January 31, 2018, $64.0 $25.0 $36.0 January 1, 2023 2.72%. 815 The following table presents the notional amount and fair value of the Company’s derivative instruments as of March 31, 2020 December 31, 2019. March 31, 2020 Notional Amount Fair Value (a) Derivatives instruments Balance sheet classification (in thousands) Interest rate swaps Other long term liabilities $ 27,289 $ (747 ) December 31, 2019 Notional Amount Fair Value (a) Derivatives instruments Balance sheet classification (in thousands) Interest rate swaps Other long term liabilities $ 28,821 $ (603 ) (a) See Note 14 All of the Company’s derivative instruments are designated as hedging instruments. The Company has structured its interest rate swap agreements to be 100% no 815, The following table summarizes the effect of derivatives designated as cash flow hedging instruments and their classification within comprehensive loss for the three March 31, 2020 2019: Derivatives in Hedging Relationships Amount of gain (loss) recognized in OCI on derivative Three Months Ended March 31, 2020 2019 (in thousands) Interest rate swaps $ (216 ) $ (196 ) The following table summarizes the reclassifications out of accumulated other comprehensive loss for the three March 31, 2020 2019: Details about AOCI Components Amount reclassified from AOCI into income Three Months Ended March 31, Location of amount reclassified from AOCI 2020 2019 into income (effective portion) (in thousands) Interest rate swaps $ 72 $ 17 Interest expense As of March 31, 2020, $0.4 twelve twelve

Note 14 - Fair Value Measuremen

Note 14 - Fair Value Measurement	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Fair Value Disclosures [Text Block]	14. Fair Value Measurement Fair value measurement is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A fair value hierarchy is established, which prioritizes the inputs used in measuring fair value into three Level 1—Quoted Level 2—Inputs, Level 3—Unobservable The following tables present the fair value hierarchy for those assets or liabilities measured at fair value on a recurring basis: Fair Value as of March 31, 2020 (in thousands) Level 1 Level 2 Level 3 Total Assets (Liabilities): Interest rate swap agreements $ - $ (747 ) $ - $ (747 ) Fair Value as of December 31, 2019 (in thousands) Level 1 Level 2 Level 3 Total Assets (Liabilities): Interest rate swap agreements $ - $ (603 ) $ - $ (603 ) The Company uses the market approach technique to value its financial liabilities. The Company’s financial assets and liabilities carried at fair value include derivative instruments used to hedge the Company’s interest rate risks. The fair value of the Company’s interest rate swap agreements was based on LIBOR yield curves at the reporting date.

Note 15 - Other Current Liabili

Note 15 - Other Current Liabilities	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Accrued Expenses Disclosure [Text Block]	15. Other Current Liabilities March 31, December 31, 2020 2019 (in thousands) Compensation and payroll $ 2,896 $ 2,554 Professional fees 567 395 Warranty costs 201 252 Local taxes, including VAT 91 345 Customer related costs 1,179 963 Interest 490 425 Other 2,025 1,157 Total $ 7,449 $ 6,091

Note 16 - Revenues

Note 16 - Revenues	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	16. Revenues The following table represents a disaggregation of revenue from contracts with customers. Revenue originating from the following geographic areas for the three March 31, 2020 2019 Three Months Ended March 31, 2020 (in thousands) United United Germany Rest of the Total Instruments, equipment, software and accessories $ 15,956 $ 2,507 $ 2,573 $ 1,901 $ 22,937 Service, maintenance and warranty contracts 575 204 39 16 834 Total revenues $ 16,531 $ 2,711 $ 2,612 $ 1,917 $ 23,771 Three Months Ended March 31, 2019 (in thousands) United United Germany Rest of the Total Instruments, equipment, software and accessories $ 18,671 $ 3,129 $ 2,913 $ 2,044 $ 26,757 Service, maintenance and warranty contracts 1,143 190 97 15 1,445 Total revenues $ 19,814 $ 3,319 $ 3,010 $ 2,059 $ 28,202 Deferred revenue The Company had approximately $3.7 March 31, 2020 2019, Three Months Ended March 31, 2020 (in thousands) Service Customer Total Balance, beginning of period $ 1,587 $ 2,362 $ 3,949 Deferral of revenue 308 223 531 Recognition of deferred revenue (499 ) (322 ) (821 ) Effect of foreign currency translation 14 - 14 Balance, end of period $ 1,410 $ 2,263 $ 3,673 Three Months Ended March 31, 2019 (in thousands) Service Customer Total Balance, beginning of period $ 1,659 $ 2,161 $ 3,820 Deferral of revenue 845 111 956 Recognition of deferred revenue (848 ) (223 ) (1,071 ) Effect of foreign currency translation 10 - 10 Balance, end of period $ 1,666 $ 2,049 $ 3,715 Allowance for Doubtful Accounts Allowance for doubtful accounts is based on the Company’s assessment of the collectability of accounts receivable. A rollforward of allowance for doubtful accounts is as follows: Three Months Ended March 31, 2020 2019 (in thousands) Balance, beginning of period $ 325 $ 332 Bad debt expense 4 348 Charge-offs and other recoveries (31 ) (337 ) Effect of foreign currency translation (1 ) (2 ) Balance, end of period $ 297 $ 341 Concentrations No 10% three March 31, 2020, 2019. March 31, 2020, 2019, no 10%

Note 17 - Income Tax

Note 17 - Income Tax	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Income Tax Disclosure [Text Block]	17. Income Tax Income tax expense was approximately $0.1 $0.6 three March 31, 2020 2019, 1.2 three March 31, 2020 32.1 2019. The difference between the Company’s effective tax rates in 2020 2019 21% 2020 2019 2020

Note 18 - Commitments and Conti

Note 18 - Commitments and Contingent Liabilities	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	18. Commitments and Contingent Liabilities On April 14, 2017, 2013, third third 2012 2013. The Company is involved in various other claims and legal proceedings arising in the ordinary course of business. Based on the consultation with the Company’s legal counsel, the ultimate disposition of such proceedings is not not not one

Note 19 - Subsequent Event

Note 19 - Subsequent Event	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Subsequent Events [Text Block]	19. Subsequent Event On April 18, 2020, $6.1 On April 23, 2020, May 4, 2020.

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The unaudited consolidated financial statements of Harvard Bioscience, Inc. and its wholly-owned subsidiaries (collectively, Harvard Bioscience or the Company) as of March 31, 2020 three March 31, 2020 2019, December 31, 2019 not not 10 December 31, 2019, March 16, 2020. In the opinion of management, all adjustments, which include normal recurring adjustments necessary to present a fair statement of financial position as of March 31, 2020, three March 31, 2020 2019 three March 31, 2020 2019, three March 31, 2020 not
Risk and Uncertainties Policy [Policy Text Block]	Risks and Uncertainties On March 11, 2020, 19 19 19 As a result of these market and economic conditions, in accordance with the guidelines set forth in ASC 350 360, March 31, 2020, no 19. 2020.

Note 3 - Accumulated Other Co_2

Note 3 - Accumulated Other Comprehensive Loss (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Foreign currency Derivatives translation qualifying as Defined benefit (in thousands) adjustments hedges pension plans Total Balance at December 31, 2019 $ (13,173 ) $ (603 ) $ 1,087 $ (12,689 ) Other comprehensive (loss) income before reclassifications (1,576 ) (216 ) (1,792 ) Amounts reclassified from AOCI into Income - 72 72 Net other comprehensive (loss) income (1,576 ) (144 ) - (1,720 ) Balance at March 31, 2020 $ (14,749 ) $ (747 ) $ 1,087 $ (14,409 )

Note 4 - Goodwill and Intangi_2

Note 4 - Goodwill and Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Goodwill [Table Text Block]	March 31, 2020 (in thousands) Balance at December 31, 2019 $ 57,381 Effect of change in currency translation (589 ) Balance at March 31, 2020 $ 56,792
Schedule of Intangible Assets and Goodwill [Table Text Block]	March 31, 2020 December 31, 2019 (in thousands) Intangible assets: Weighted Gross Accumulated Net Gross Accumulated Net Distribution agreements/customer relationships 8.4 $ 17,685 $ (6,550 ) $ 11,135 $ 17,891 $ (6,340 ) $ 11,551 Existing technology 5.5 40,923 (20,327 ) 20,596 41,222 (19,698 ) 21,524 Trade names 5.3 8,511 (3,667 ) 4,844 7,692 (3,497 ) 4,195 Patents - 206 (206 ) - 218 (218 ) - Indefinite-lived tradename NA 232 - 232 1,135 0 1,135 Total intangible assets $ 67,557 $ (30,750 ) $ 36,807 $ 68,158 $ (29,753 ) $ 38,405

Note 5 - Inventories (Tables)

Note 5 - Inventories (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Inventory, Current [Table Text Block]	March 31, December 31, (in thousands) Finished goods $ 5,280 $ 5,561 Work in process 3,160 3,153 Raw materials 14,703 13,347 Total $ 23,143 $ 22,061

Note 6 - Property, Plant and _2

Note 6 - Property, Plant and Equipment (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Property, Plant and Equipment [Table Text Block]	March 31, December 31, (in thousands) Machinery and equipment $ 7,437 $ 7,198 Computer equipment and software 8,763 8,954 Leasehold improvements 2,157 2,151 Furniture and fixtures 1,309 1,321 Automobiles 90 92 19,756 19,716 Less: accumulated depreciation (15,268 ) (14,940 ) Property, plant and equipment, net $ 4,488 $ 4,776

Note 7 - Restructuring and Ot_2

Note 7 - Restructuring and Other Exit Costs (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Restructuring Reserve by Type of Cost [Table Text Block]	(in thousands) Severance Other Total Balance at December 31, 2019 $ 364 $ 4 $ 368 Restructuring charges 834 40 874 Adjustments (45 ) - (45 ) Cash payments (569 ) (36 ) (605 ) Balance at March 31, 2020 $ 584 $ 8 $ 592

Note 10 - Leases (Tables)

Note 10 - Leases (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Lease, Cost [Table Text Block]	Three Months Ended Three Months Ended March 31, 2020 March 31, 2019 (in thousands) (in thousands) Operating lease cost $ 535 $ 523 Short term lease cost 42 76 Sublease income (107 ) (102 ) Total lease cost $ 470 $ 497
Supplemental Cash Flow Information Related to Operating Leases [Table Text Block]	Three Months Ended Three Months Ended March 31, 2020 March 31, 2019 (in thousands) (in thousands) Cash paid for amounts included in the measurement $ 687 $ 702
Supplemental Balance Sheet Informaton Related to Operating Leases [Table Text Block]	March 31, 2020 December 31, 2019 (in thousands) (in thousands) Operating lease right-of use assets $ 8,127 $ 8,463 Current portion, operating lease liabilities $ 2,297 $ 2,424 Operating lease liabilities, long term 7,867 8,224 Total operating lease liabilities $ 10,164 $ 10,648 Weighted average remaining lease term (in years) 8.0 8.1 Weighted average discount rate 9.2 % 9.2 %
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Operating Leases (in thousands) 2021 $ 2,297 2022 1,905 2023 1,842 2024 1,827 2025 1,367 Thereafter 5,574 Total lease payments 14,812 Less interest (4,648 ) Total operating lease liabilities $ 10,164

Note 11 - Capital Stock and S_2

Note 11 - Capital Stock and Stock-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule Of Stock Options And Restricted Stock Units Activity Roll forward [Table Text Block]	Stock Options Restricted Stock Units Market Condition RSU's Weighted Stock Average Restricted Market Options Exercise Stock Units Grant Date Condition RSU's Grant Date Outstanding Price Outstanding Fair Value Outstanding Fair Value Balance at December 31, 2019 2,266,122 $ 3.93 1,590,450 $ 2.27 529,491 $ 1.67 Granted 42,373 2.58 142,766 3.00 - - Vested (RSUs) - - (267,588 ) 2.75 - - Cancelled / forfeited (49,074 ) 3.81 (31,795 ) 3.02 - - Balance at March 31, 2020 2,259,421 $ 3.90 1,433,833 $ 2.24 529,491 $ 1.67
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended March 31, 2020 2019 (in thousands) Cost of product revenues $ 10 $ 13 Sales and marketing 51 (7 ) General and administrative 696 551 Research and development 36 34 Total stock-based compensation $ 793 $ 591
Schedule of Weighted Average Number of Shares [Table Text Block]	Three Months Ended March 31, 2020 2019 Basic 38,328,791 37,644,684 Diluted 38,328,791 37,644,684
Black Scholes Option Pricing Model [Member]
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2020 Volatility 54.83 % Risk-free interest rate 1.16 % Expected holding period (in years) 4.6

Note 12 - Long Term Debt (Table

Note 12 - Long Term Debt (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Debt [Table Text Block]	March 31, December 31, 2020 2019 (in thousands) Long-term debt: Term loan $ 50,168 54,997 Revolving line - - Total unamortized deferred financing costs (1,081 ) (1,180 ) Total debt 49,087 53,817 Less: current installments (3,200 ) (3,200 ) Less: excess cash flow sweep - (4,093 ) Current unamortized deferred financing costs 393 393 Long-term debt $ 46,280 $ 46,917

Note 13 - Derivatives (Tables)

Note 13 - Derivatives (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]	March 31, 2020 Notional Amount Fair Value (a) Derivatives instruments Balance sheet classification (in thousands) Interest rate swaps Other long term liabilities $ 27,289 $ (747 ) December 31, 2019 Notional Amount Fair Value (a) Derivatives instruments Balance sheet classification (in thousands) Interest rate swaps Other long term liabilities $ 28,821 $ (603 )
Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Derivatives in Hedging Relationships Amount of gain (loss) recognized in OCI on derivative Three Months Ended March 31, 2020 2019 (in thousands) Interest rate swaps $ (216 ) $ (196 ) Details about AOCI Components Amount reclassified from AOCI into income Three Months Ended March 31, Location of amount reclassified from AOCI 2020 2019 into income (effective portion) (in thousands) Interest rate swaps $ 72 $ 17 Interest expense

Note 14 - Fair Value Measurem_2

Note 14 - Fair Value Measurement (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Fair Value as of March 31, 2020 (in thousands) Level 1 Level 2 Level 3 Total Assets (Liabilities): Interest rate swap agreements $ - $ (747 ) $ - $ (747 ) Fair Value as of December 31, 2019 (in thousands) Level 1 Level 2 Level 3 Total Assets (Liabilities): Interest rate swap agreements $ - $ (603 ) $ - $ (603 )

Note 15 - Other Current Liabi_2

Note 15 - Other Current Liabilities (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	March 31, December 31, 2020 2019 (in thousands) Compensation and payroll $ 2,896 $ 2,554 Professional fees 567 395 Warranty costs 201 252 Local taxes, including VAT 91 345 Customer related costs 1,179 963 Interest 490 425 Other 2,025 1,157 Total $ 7,449 $ 6,091

Note 16 - Revenues (Tables)

Note 16 - Revenues (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Months Ended March 31, 2020 (in thousands) United United Germany Rest of the Total Instruments, equipment, software and accessories $ 15,956 $ 2,507 $ 2,573 $ 1,901 $ 22,937 Service, maintenance and warranty contracts 575 204 39 16 834 Total revenues $ 16,531 $ 2,711 $ 2,612 $ 1,917 $ 23,771 Three Months Ended March 31, 2019 (in thousands) United United Germany Rest of the Total Instruments, equipment, software and accessories $ 18,671 $ 3,129 $ 2,913 $ 2,044 $ 26,757 Service, maintenance and warranty contracts 1,143 190 97 15 1,445 Total revenues $ 19,814 $ 3,319 $ 3,010 $ 2,059 $ 28,202
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]	Three Months Ended March 31, 2020 (in thousands) Service Customer Total Balance, beginning of period $ 1,587 $ 2,362 $ 3,949 Deferral of revenue 308 223 531 Recognition of deferred revenue (499 ) (322 ) (821 ) Effect of foreign currency translation 14 - 14 Balance, end of period $ 1,410 $ 2,263 $ 3,673 Three Months Ended March 31, 2019 (in thousands) Service Customer Total Balance, beginning of period $ 1,659 $ 2,161 $ 3,820 Deferral of revenue 845 111 956 Recognition of deferred revenue (848 ) (223 ) (1,071 ) Effect of foreign currency translation 10 - 10 Balance, end of period $ 1,666 $ 2,049 $ 3,715
Financing Receivable, Allowance for Credit Loss [Table Text Block]	Three Months Ended March 31, 2020 2019 (in thousands) Balance, beginning of period $ 325 $ 332 Bad debt expense 4 348 Charge-offs and other recoveries (31 ) (337 ) Effect of foreign currency translation (1 ) (2 ) Balance, end of period $ 297 $ 341

Note 1 - Basis of Presentatio_2

Note 1 - Basis of Presentation, Risks and Uncertainties, and Summary of Significant Accounting Policies (Details Textual) $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)
COVID-19 [Member]
Asset Impairment Charges, Total	$ 0

Note 3 - Accumulated Other Co_3

Note 3 - Accumulated Other Comprehensive Loss - Changes in Each Component of Other Comprehensive Loss, Net of Tax (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Balance	$ 81,694	$ 82,724
Other comprehensive (loss)	(1,720)	(175)
Balance	76,009	80,349
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]
Balance	(13,173)
Other comprehensive (loss) income before reclassifications	(1,576)
Amounts reclassified from AOCI into Income
Other comprehensive (loss)	(1,576)
Balance	(14,749)
Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]
Balance	(603)
Other comprehensive (loss) income before reclassifications	(216)
Amounts reclassified from AOCI into Income	72
Other comprehensive (loss)	(144)
Balance	(747)
Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]
Balance	1,087
Other comprehensive (loss) income before reclassifications
Amounts reclassified from AOCI into Income
Other comprehensive (loss)
Balance	1,087
AOCI Attributable to Parent [Member]
Balance	(12,689)	(13,532)
Other comprehensive (loss) income before reclassifications	(1,792)
Amounts reclassified from AOCI into Income	72
Other comprehensive (loss)	(1,720)	(175)
Balance	$ (14,409)	$ (13,707)

Note 4 - Goodwill and Intangi_3

Note 4 - Goodwill and Intangible Assets (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Amortization of Intangible Assets, Total	$ 1,427	$ 1,430
Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year	4,100
Finite-Lived Intangible Asset, Expected Amortization, Year Two	5,500
Finite-Lived Intangible Asset, Expected Amortization, Year Three	5,500
Finite-Lived Intangible Asset, Expected Amortization, Year Four	5,300
Finite-Lived Intangible Asset, Expected Amortization, Year Five	5,300
Finite-Lived Intangible Asset, Expected Amortization, Year Six	4,200
Indefinite-Lived Trade Names Reclassified to Finite-Lived [Member]
Reclassification of Intangible Assets	$ 900
Finite-Lived Intangible Asset, Useful Life (Year)	4 years

Note 4 - Goodwill and Intangi_4

Note 4 - Goodwill and Intangible Assets - Change in Carrying Amount of Goodwill (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)
Balance at December 31, 2019	$ 57,381
Effect of change in currency translation	(589)
Balance at March 31, 2020	$ 56,792

Note 4 - Goodwill and Intangi_5

Note 4 - Goodwill and Intangible Assets - Intangible Assets (Details) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2020	Dec. 31, 2019
Total amortizable intangible assets		$ (30,750)	$ (29,753)
Indefinite-lived tradename		232	1,135
Total Intangible Assets, Gross		67,557	68,158
Intangible assets, net		$ 36,807	38,405
Distribution Agreements/Customer Relationships [Member]
Finite-Lived Intangible Assets, Weighted Average Useful Life (Year)	[1]	8 years 146 days
Finite-Lived Intangible Assets, Gross		$ 17,685	17,891
Total amortizable intangible assets		(6,550)	(6,340)
Finite-Lived Intangible Assets, Net		$ 11,135	11,551
Existing Technology [Member]
Finite-Lived Intangible Assets, Weighted Average Useful Life (Year)	[1]	5 years 182 days
Finite-Lived Intangible Assets, Gross		$ 40,923	41,222
Total amortizable intangible assets		(20,327)	(19,698)
Finite-Lived Intangible Assets, Net		$ 20,596	21,524
Trade Names [Member]
Finite-Lived Intangible Assets, Weighted Average Useful Life (Year)	[1]	5 years 109 days
Finite-Lived Intangible Assets, Gross		$ 8,511	7,692
Total amortizable intangible assets		(3,667)	(3,497)
Finite-Lived Intangible Assets, Net		4,844	4,195
Patents [Member]
Finite-Lived Intangible Assets, Gross		206	218
Total amortizable intangible assets		(206)	(218)
Finite-Lived Intangible Assets, Net
[1]	Weighted average life as of March 31, 2020.

Note 5 - Inventories - Inventor

Note 5 - Inventories - Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Finished goods	$ 5,280	$ 5,561
Work in process	3,160	3,153
Raw materials	14,703	13,347
Total	$ 23,143	$ 22,061

Note 6 - Property, Plant and _3

Note 6 - Property, Plant and Equipment - Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment, Gross	$ 19,756	$ 19,716
Less: accumulated depreciation	(15,268)	(14,940)
Property, plant and equipment, net	4,488	4,776
Machinery and Equipment [Member]
Property, Plant and Equipment, Gross	7,437	7,198
Computer Equipment and Software [member]
Property, Plant and Equipment, Gross	8,763	8,954
Leasehold Improvements [Member]
Property, Plant and Equipment, Gross	2,157	2,151
Furniture and Fixtures [Member]
Property, Plant and Equipment, Gross	1,309	1,321
Automobiles [Member]
Property, Plant and Equipment, Gross	$ 90	$ 92

Note 7 - Restructuring and Ot_3

Note 7 - Restructuring and Other Exit Costs (Details Textual) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Restructuring Reserve, Ending Balance	$ 592	$ 368

Note 7 - Restructuring and Ot_4

Note 7 - Restructuring and Other Exit Costs - Activity for Accrued Restructuring Liability (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)
Balance at December 31, 2019	$ 368
Restructuring charges	874
Adjustments	(45)
Cash payments	(605)
Balance at March 31, 2020	592
Employee Severance [Member]
Balance at December 31, 2019	364
Restructuring charges	834
Adjustments	(45)
Cash payments	(569)
Balance at March 31, 2020	584
Other Restructuring [Member]
Balance at December 31, 2019	4
Restructuring charges	40
Adjustments
Cash payments	(36)
Balance at March 31, 2020	$ 8

Note 8 - Related Party Transa_2

Note 8 - Related Party Transactions (Details Textual) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Multi Channel Systems MCS GmbH [Member]
Operating Leases, Rent Expense, Net, Total	$ 0.1	$ 0.1

Note 9 - Employee Benefit Pla_2

Note 9 - Employee Benefit Plans (Details Textual) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Defined Contribution Plan, Cost	$ 0.1	$ 0.2
Defined Benefit Plan, Plan Assets, Contributions by Employer	0.2
Defined Benefit Plan, Expected Future Benefit Payment, Year Four	0.7
Other Noncurrent Assets [Member]
Defined Benefit Plan, Plan Assets, Amount, Ending Balance	$ 1.1

Note 10 - Leases - Lease Expens

Note 10 - Leases - Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Operating lease cost	$ 535	$ 523
Short term lease cost	42	76
Sublease income	(107)	(102)
Total lease cost	$ 470	$ 497

Note 10 - Leases - Supplemental

Note 10 - Leases - Supplemental Cash Flow Information Related to Operating Leases (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash paid for amounts included in the measurement of lease liabilities:	$ 687	$ 702

Note 10 - Leases - Supplement_2

Note 10 - Leases - Supplemental Balance Sheet Information Related to Operating Leases (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Operating lease right-of use assets	$ 8,127	$ 8,463
Current portion, operating lease liabilities	2,297	2,424
Operating lease liabilities, long term	7,867	8,224
Total operating lease liabilities	$ 10,164	$ 10,648
Weighted average remaining lease term (in years) (Year)	8 years	8 years 36 days
Weighted average discount rate	9.20%	9.20%

Note 10 - Leases - Future Minim

Note 10 - Leases - Future Minimum Lease Payments (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
2021	$ 2,297
2022	1,905
2023	1,842
2024	1,827
2025	1,367
Thereafter	5,574
Total lease payments	14,812
Less interest	(4,648)
Total operating lease liabilities	$ 10,164	$ 10,648

Note 11 - Capital Stock and S_3

Note 11 - Capital Stock and Stock-based Compensation (Details Textual) - USD ($) $ / shares in Units, $ in Millions	May 16, 2019	Apr. 02, 2018	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2000	Dec. 31, 2019	May 18, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date					85.00%
Increase In Number Of Shares Authorized For Issuance Under Stock Option And Incentive Plan (in shares)	350,000	3,400,000
Employee Stock Purchase Plan Shares Authorized (in shares)							1,400,000
Employee Stock Ownership Plan (ESOP), Shares in ESOP, Total (in shares)						1,081,404
Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares)			0
Employee Stock Ownership Plan, Shares Available for Issuance (in shares)			318,596
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)		20,908,929	275,419
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total			$ 3.3
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)			2 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)			$ 1.18
Deferred Compensation Arrangement with Individual, Maximum Contractual Term (Year)			10 years
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)			4,222,745	3,691,304
Deferred stock awards of Market Condition RSU, Approved 2019 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)			529,491
Maximum Percentage Of Target, Number of Restricted Stock Units			150.00%
Share-based Payment Arrangement, Option [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)			1 year
Share-based Payment Arrangement, Option [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)			4 years

Note 11 - Capital Stock and S_4

Note 11 - Capital Stock and Stock-based Compensation - Stock Option and Restricted Stock Unit Activity (Details)	3 Months Ended
	Mar. 31, 2020$ / sharesshares
Opening Balance, Stock Options Outstanding (in shares) | shares	2,266,122
Options, Outstanding, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 3.93
Options, Granted in Period (in shares) | shares	42,373
Options, Granted in Period, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 2.58
Options, Cancelled / Forfeited in Period (in shares) | shares	(49,074)
Options, Cancelled / Forfeited, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 3.81
Opening Balance, Stock Options Outstanding (in shares) | shares	2,259,421
Options, Outstanding, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 3.90
Restricted Stock Units (RSUs) [Member]
Restricted Stock Units Outstanding , Balance (in shares) | shares	1,590,450
Restricted Stock Units Outstanding , Grant Date Fair Value, Balance (in dollars per share) | $ / shares	$ 2.27
Restricted Stock Units, Granted in Period (in shares) | shares	142,766
Restricted Stock Units Granted , Grant Date Fair Value, Balance (in dollars per share) | $ / shares	$ 3
Restricted Stock Units, Vested in Period (in shares) | shares	(267,588)
Restricted Stock Units, Vested , Grant Date Fair Value, Balance (in dollars per share) | $ / shares	$ 2.75
Restricted Stock Units, Cancelled / Forfeited in Period (in shares) | shares	(31,795)
Restricted Stock Units, Cancelled/ Forfeited , Grant Date Fair Value, Balance (in dollars per share) | $ / shares	$ 3.02
Restricted Stock Units Outstanding , Balance (in shares) | shares	1,433,833
Restricted Stock Units Outstanding , Grant Date Fair Value, Balance (in dollars per share) | $ / shares	$ 2.24
Market Condition Restricted Stock Units [Member]
Restricted Stock Units Outstanding , Balance (in shares) | shares	529,491
Restricted Stock Units Outstanding , Grant Date Fair Value, Balance (in dollars per share) | $ / shares	$ 1.67
Restricted Stock Units, Granted in Period (in shares) | shares
Restricted Stock Units Granted , Grant Date Fair Value, Balance (in dollars per share) | $ / shares
Restricted Stock Units, Vested in Period (in shares) | shares
Restricted Stock Units, Vested , Grant Date Fair Value, Balance (in dollars per share) | $ / shares
Restricted Stock Units, Cancelled / Forfeited in Period (in shares) | shares
Restricted Stock Units, Cancelled/ Forfeited , Grant Date Fair Value, Balance (in dollars per share) | $ / shares
Restricted Stock Units Outstanding , Balance (in shares) | shares	529,491
Restricted Stock Units Outstanding , Grant Date Fair Value, Balance (in dollars per share) | $ / shares	$ 1.67

Note 11 - Capital Stock and S_5

Note 11 - Capital Stock and Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Share-based Compensation	$ 793	$ 591
Cost of Sales [Member] | Continuing Operations [Member]
Share-based Compensation	10	13
Selling and Marketing Expense [Member] | Continuing Operations [Member]
Share-based Compensation	51	(7)
General and Administrative Expense [Member] | Continuing Operations [Member]
Share-based Compensation	696	551
Research and Development Expense [Member] | Continuing Operations [Member]
Share-based Compensation	$ 36	$ 34

Note 11 - Capital Stock and S_6

Note 11 - Capital Stock and Stock-based Compensation - Black Scholes Assumptions (Details) - Black Scholes Option Pricing Model [Member]	3 Months Ended
	Mar. 31, 2020
Volatility	54.83%
Risk-free interest rate	1.16%
Expected holding period (Year)	4 years 219 days

Note 11 - Capital Stock and S_7

Note 11 - Capital Stock and Stock-based Compensation - Weighted Average Number of Shares (Details) - shares	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Basic (in shares)	38,328,791	37,644,684
Diluted (in shares)	38,328,791	37,644,684

Note 12 - Long Term Debt (Detai

Note 12 - Long Term Debt (Details Textual) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Jun. 30, 2020	Mar. 31, 2018USD ($)	Jan. 31, 2018USD ($)
Term Loan [Member]
Line of Credit Facility, Interest Rate at Period End	8.40%
Senior Secured Credit Facility [Member]
Debt Instrument, Quarterly Payment, Current Year				$ 400
Debt Instrument Quarterly Payment Next Year				600
Debt Instrument, Quarterly Payment, Thereafter				$ 800
Percentage of Consolidated Excess Cash Flow				50.00%
Excess Cash Flow Payment	$ 4,000
Excess Cash Flow Payment, Tranche Two		$ 4,000
Excess Cash Flow Payment, Tranche One		1,000
Limitation On Pledges of Capital Stock of Foreign Subsidiaries	65.00%
Senior Secured Credit Facility [Member] | Maximum [Member]
Debt Instrument, Leverage Ratio	3.5
Senior Secured Credit Facility [Member] | Maximum [Member] | Forecast [Member]
Debt Instrument, Leverage Ratio			3.25
Senior Secured Credit Facility [Member] | Base Rate [Member]
Debt Instrument, Basis Spread on Variable Rate	4.75%
Senior Secured Credit Facility [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate	6.25%
Senior Secured Credit Facility [Member] | London Interbank Offered Rate (LIBOR) [Member] | Minimum [Member]
Debt Instrument, Interest Rate, Stated Percentage	1.25%
Senior Secured Credit Facility [Member] | London Interbank Offered Rate (LIBOR) [Member] | Maximum [Member]
Debt Instrument, Interest Rate, Stated Percentage	4.25%
Senior Secured Credit Facility [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity					$ 25,000
Line of Credit Facility, Remaining Borrowing Capacity	$ 4,600
Term Loan [Member]
Long-term Debt, Gross	$ 50,168	$ 54,997
Term Loan [Member] | Senior Secured Credit Facility [Member]
Long-term Debt, Gross					$ 64,000

Note 12 - Long Term Debt - Brea

Note 12 - Long Term Debt - Breakdown of Borrowings (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Total unamortized deferred financing costs	$ (1,081)	$ (1,180)
Total debt	49,087	53,817
Less: current installments	(3,200)	(3,200)
Less: excess cash flow sweep		(4,093)
Current unamortized deferred financing costs	393	393
Long-term debt	46,280	46,917
Term Loan [Member]
Long-term debt, gross	50,168	54,997
Line of Credit [Member]
Long-term debt, gross

Note 13 - Derivatives (Details

Note 13 - Derivatives (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019	Jan. 31, 2018
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	$ 400
Interest Rate Swap [Member] | London Interbank Offered Rate (LIBOR) [Member]
Derivative, Fixed Interest Rate			2.72%
Interest Rate Swap [Member] | PNC Bank [Member]
Derivative Asset, Notional Amount			$ 36,000
Term Loan [Member]
Long-term Debt, Gross	$ 50,168	$ 54,997
Senior Secured Credit Facility [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity			25,000
Senior Secured Credit Facility [Member] | Term Loan [Member]
Long-term Debt, Gross			$ 64,000

Note 13 - Derivatives - Derivat

Note 13 - Derivatives - Derivative Instruments (Details) - Interest Rate Swap [Member] - Cash Flow Hedging [Member] - USD ($) $ in Thousands		Mar. 31, 2020	Dec. 31, 2019
Other Noncurrent Liabilities [Member]
Derivatives, notional amount		$ 27,289
Derivatives, fair value	[1]	$ (747)
Other Assets [Member]
Derivatives, notional amount			$ 28,821
Derivatives, fair value	[1]		$ (603)
[1]	See Note 14 for the fair value measurements related to these financial instruments.

Note 13 - Derivatives - Effect

Note 13 - Derivatives - Effect of Derivatives on AOCI (Details) - Interest Rate Swap [Member] - Cash Flow Hedging [Member] - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Amount of loss recognized in OCI on derivative	$ (216)	$ (196)
Interest Expense [Member]
Amount reclassified from AOCI into income	$ 72	$ 17

Note 14 - Fair Value Measurem_3

Note 14 - Fair Value Measurement - Assets and Liabilities Measured on a Recurring Basis (Details) - Interest Rate Swap [Member] - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Derivative liabilities	$ (747)	$ (603)
Fair Value, Inputs, Level 1 [Member]
Derivative liabilities
Fair Value, Inputs, Level 2 [Member]
Derivative liabilities	(747)	(603)
Fair Value, Inputs, Level 3 [Member]
Derivative liabilities

Note 15 - Other Current Liabi_3

Note 15 - Other Current Liabilities - Accrued Expenses (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Compensation and payroll	$ 2,896	$ 2,554
Professional fees	567	395
Warranty costs	201	252
Local taxes, including VAT	91	345
Customer related costs	1,179	963
Interest	490	425
Other	2,025	1,157
Total	$ 7,449	$ 6,091

Note 16 - Revenues (Details Tex

Note 16 - Revenues (Details Textual) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019	Mar. 31, 2019	Dec. 31, 2018
Contract with Customer, Liability, Total	$ 3,673	$ 3,949	$ 3,715	$ 3,820

Note 16 - Revenues - Disaggrega

Note 16 - Revenues - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Total revenues	$ 23,771	$ 28,202
Instruments, Equipment, Software, and Accessories [Member]
Total revenues	22,937	26,757
Service, Maintenance, and Warranty Contracts [Member]
Total revenues	834	1,445
UNITED STATES
Total revenues	16,531	19,814
UNITED STATES | Instruments, Equipment, Software, and Accessories [Member]
Total revenues	15,956	18,671
UNITED STATES | Service, Maintenance, and Warranty Contracts [Member]
Total revenues	575	1,143
UNITED KINGDOM
Total revenues	2,711	3,319
UNITED KINGDOM | Instruments, Equipment, Software, and Accessories [Member]
Total revenues	2,507	3,129
UNITED KINGDOM | Service, Maintenance, and Warranty Contracts [Member]
Total revenues	204	190
GERMANY
Total revenues	2,612	3,010
GERMANY | Instruments, Equipment, Software, and Accessories [Member]
Total revenues	2,573	2,913
GERMANY | Service, Maintenance, and Warranty Contracts [Member]
Total revenues	39	97
Rest of the World [Member]
Total revenues	1,917	2,059
Rest of the World [Member] | Instruments, Equipment, Software, and Accessories [Member]
Total revenues	1,901	2,044
Rest of the World [Member] | Service, Maintenance, and Warranty Contracts [Member]
Total revenues	$ 16	$ 15

Note 16 - Revenues - Changes in

Note 16 - Revenues - Changes in Deferred Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Balance	$ 3,949	$ 3,820
Deferral of revenue	531	956
Recognition of deferred revenue	(821)	(1,071)
Effect of foreign currency translation	14	10
Balance	3,673	3,715
Service [Member]
Balance	1,587	1,659
Deferral of revenue	308	845
Recognition of deferred revenue	(499)	(848)
Effect of foreign currency translation	14	10
Balance	1,410	1,666
Customer Advances [Member]
Balance	2,362	2,161
Deferral of revenue	223	111
Recognition of deferred revenue	(322)	(223)
Effect of foreign currency translation
Balance	$ 2,263	$ 2,049

Note 16 - Revenues - Allowance

Note 16 - Revenues - Allowance for Doubtful Accounts (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Balance, beginning of period	$ 325	$ 332
Provision for allowance for doubtful accounts	4	348
Charge-offs and other recoveries	(31)	(337)
Effect of foreign currency translation	(1)	(2)
Balance, end of period	$ 297	$ 341

Note 17 - Income Tax (Details T

Note 17 - Income Tax (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Tax Expense (Benefit), Total	$ 55	$ 576
Effective Income Tax Rate Reconciliation, Percent, Total	(1.20%)	(32.10%)

Note 19 - Subsequent Event (Det

Note 19 - Subsequent Event (Details Textual) $ in Millions	Apr. 18, 2020USD ($)
Subsequent Event [Member]
Proceeds From Paycheck Protection Program Under CARES Act	$ 6.1